Overcoming immunogenicity and safety challenges in oncology biologics
From navigating preclinical and clinical immunogenicity testing to adopting innovative assay methodologies, the report explores key challenges and opportunities in the field. Learn how a flexible approach to neutralizing antibody assays, shifting regulatory perspectives, and emerging AI-driven technologies are influencing the future of biologic drug development.
With contributions from top industry leaders, this report is a must-read for biopharmaceutical professionals seeking to refine their immunogenicity strategies. Gain practical insights into overcoming operational hurdles, optimizing assay selection, and aligning with regulatory expectations to drive progress in oncology therapeutics. Download the full report to stay at the forefront of the evolving biologics and biosimilars landscape.